🇺🇸 FDA

Intelligence · Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.

Programs
186

Quick answer

First People's Hospital has 186 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. "Nefecon®","Ambrisentan"

    The First People's Hospital of Lianyungang

    IgA Nephropathy

    approved small molecule active

    1 trial

  2. 20mg Febuxostat

    The First People's Hospital of Lianyungang

    Hyperuricemia

    approved small molecule active

    1 trial

  3. 37.5mg Pregabalin + 75mg Pregabalin

    The First People's Hospital of Lianyungang

    Pain, Postoperative

    approved small molecule completed

    1 trial

  4. ALA

    The First People's Hospital of Lianyungang

    Actinic Keratoses

    approved small molecule active

    1 trial

  5. AN69ST hemofilter

    The First People's Hospital of Lianyungang

    Critical Ill Patients

    approved other completed

    1 trial

  6. Aerosolized 13 cis retinoic acid plus Vitamin D

    The First People's Hospital of Lianyungang

    Post COVID-19 Anosmia (Loss of Smell)

    approved small molecule active

    1 trial

  7. Alprostadil

    The First People's Hospital of Lianyungang

    Stroke

    approved small molecule active

    1 trial

  8. Amlodipine besylate

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  9. Anti-peristaltic ileosigmoid anastomosis

    The First People's Hospital of Lianyungang

    Constipation

    approved other completed

    1 trial

  10. Aspirin

    The First People's Hospital of Lianyungang

    Recurrent Pregnancy Loss

    approved small molecule active

    1 trial

  11. Aspirin

    The First People's Hospital of Lianyungang

    G6PD Deficiency

    approved small molecule active

    1 trial

  12. Azvudine

    The First People's Hospital of Lianyungang

    COVID-19

    approved small molecule active

    1 trial

  13. Babaodan oral capsule

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  14. Basiliximab

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    1 trial

  15. Basiliximab,

    The First People's Hospital of Lianyungang

    Beta-Thalassemia Major

    approved small molecule completed

    1 trial

  16. Berberine

    The First People's Hospital of Lianyungang

    Diabetes Mellitus

    approved small molecule completed

    1 trial

  17. Blinatumomab

    The First People's Hospital of Lianyungang

    Acute B-cell Lymphoblastic Leukemia

    approved small molecule active

    1 trial

  18. Budesonide 200 microgram/Puff, HFA MDI

    The First People's Hospital of Lianyungang

    Asthma

    approved small molecule completed

    1 trial

  19. Bupivacaine Hydrochloride

    The First People's Hospital of Lianyungang

    Pulmonary Nodule

    approved small molecule active

    1 trial

  20. Busulfan

    The First People's Hospital of Lianyungang

    Thalassemia Major

    approved small molecule completed

    1 trial

  21. Butylphthalide

    The First People's Hospital of Lianyungang

    Focal Epilepsy

    approved small molecule active

    1 trial

  22. CFNB group

    The First People's Hospital of Lianyungang

    Postoperative Pain

    approved other active

    1 trial

  23. CSII

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  24. CTB group

    The First People's Hospital of Lianyungang

    Post-operative Pain

    approved other active

    1 trial

  25. Calcitriol

    The First People's Hospital of Lianyungang

    Glomerulonephritis

    approved small molecule active

    1 trial

  26. Chemoembolization and Response-Dependent Resection

    The First People's Hospital of Lianyungang

    Resectable Hepatocellular Carcinoma Beyond Milan Criteria

    approved other active

    1 trial

  27. Cholecalciferol

    The First People's Hospital of Lianyungang

    Peritoneal Dialysis-associated Peritonitis

    approved small molecule active

    1 trial

  28. Cilostazol

    The First People's Hospital of Lianyungang

    Cerebral Small Vessel Disease

    approved small molecule active

    1 trial

  29. Cinobufacini injection

    The First People's Hospital of Lianyungang

    Liver Cancer

    approved small molecule active

    1 trial

  30. Ciprofol

    The First People's Hospital of Lianyungang

    ECMO Treatment

    approved small molecule active

    1 trial

  31. Ciprofol

    The First People's Hospital of Lianyungang

    Postoperative Delirium (POD)

    approved small molecule active

    1 trial

  32. Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses

    The First People's Hospital of Lianyungang

    HER2 Positive Breast Cancer

    approved small molecule active

    1 trial

  33. Combination of antiplatelet drugs and anticoagulants for at least one month

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule active

    1 trial

  34. Dabigatran Etexilate

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial

  35. Dapagliflozin 10 MG

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  36. Daphnetin

    The First People's Hospital of Lianyungang

    Lower Extremity Lymphedema

    approved small molecule active

    1 trial

  37. Dental foam "Biorepair PERIBIOMA"

    The First People's Hospital of Lianyungang

    Oral Health

    approved small molecule completed

    1 trial

  38. Desmopressin

    The First People's Hospital of Lianyungang

    Patients Undergoing Endoscopic Sinus Surgery

    approved small molecule completed

    1 trial

  39. Dex-Esk

    The First People's Hospital of Lianyungang

    Older Patients

    approved small molecule active

    1 trial

  40. Dexamethasone

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    approved small molecule terminated

    1 trial

  41. Dexamethasone

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial

  42. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule completed

    1 trial

  43. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Obstructive Sleep Apnea

    approved small molecule completed

    1 trial

  44. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Elderly

    approved small molecule completed

    3 trials

  45. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Overall Survival

    approved small molecule completed

    1 trial

  46. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Postoperative Delirium After Living Donor Renal Transplantation

    approved small molecule active

    1 trial

  47. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Older Patients

    approved small molecule active

    1 trial

  48. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Renal Function

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

186 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.